Status:
COMPLETED
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE)
Lead Sponsor:
University of Thessaly
Conditions:
Surgery--Complications
Eligibility:
All Genders
18+ years
Brief Summary
In critically ill patients, the soluble urokinase plasminogen activator receptor (suPAR) level is significantly increased. suPAR is an independent prognostic marker, and the change over time correlate...
Detailed Description
BACKGROUND Soluble urokinase plasminogen activator receptor The biomarker soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the cell membrane-bound protein urokinase pl...
Eligibility Criteria
Inclusion
- All operative approaches
- Age ≥ 18 years
- American Society of Anesthesiologists' (ASA) physical status I to IV
Exclusion
- Age \<18 years
- Any infection within the previous 4 weeks
- Severe liver disease
- Renal replacement therapy pre-operatively
- Previously received transplant
- Allergies
- Inflammatory disorders
- Immune system disorders
- Connective tissue disease
- Administration of opioids during the past week
- Asthma
- Obesity (BMI ≥ 30 kg m-2)
- Mental disability
- Severe psychiatric disease
- Alcohol or other abuse,
- Legal incapacity or limited legal capacity
- Subjects within the exclusion period of another study
Key Trial Info
Start Date :
April 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 5 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03851965
Start Date
April 15 2019
End Date
November 5 2020
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Larisa, Department of Anesthesiology
Larissa, Thessaly, Greece, 41110